Clinical Trials Logo

Gitelman Syndrome clinical trials

View clinical trials related to Gitelman Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT06065852 Recruiting - Fabry Disease Clinical Trials

National Registry of Rare Kidney Diseases

RaDaR
Start date: November 6, 2009
Phase:
Study type: Observational [Patient Registry]

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: - Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. - Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. - Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

NCT ID: NCT04995627 Recruiting - Gitelman Syndrome Clinical Trials

Salt Supplementation in Gitelman Syndrome

Start date: April 19, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum potassium and clinical signs and symptoms in patients with Gitelman syndrome.

NCT ID: NCT02297048 Completed - Gitelman Syndrome Clinical Trials

Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)

DEPROGE
Start date: July 2014
Phase: Phase 4
Study type: Interventional

Progesterone is needed to permit adaptation of the kidney to limit potassium loss in the urines. The investigators wonder whether progesterone or other adrenal hormon play the same role. The investigators will investigate surrenal hormone production in healthy subjects under a 7-day potassium depleted diet and in patients chronically hypokalaemic due to a renal loss of potassium.

NCT ID: NCT02035046 Completed - Clinical trials for Heterozygous Carriers of Gitelman Syndrome

Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter

HEPHYGI
Start date: December 2013
Phase: N/A
Study type: Interventional

Gitelman syndrome is a salt wasting tubulopathy caused by mutations in the SLC12A3 gene coding for the thiazide sensitive sodium chloride cotransporter. This disease mimics the chronic treatment with thiazide diuretics and is characterized by renal hypokalemia, low to normal blood pressure, hypocalciuria and hypomagnesemia. The purpose of this study is to determine whether the heterozygous carriers present the metabolic risks and/or the benefits of this disease.

NCT ID: NCT01146197 Completed - Gitelman Syndrome Clinical Trials

Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics

GITAB
Start date: February 2010
Phase: Phase 1/Phase 2
Study type: Interventional

Gitelman syndrome is a rare renal disease where the kidneys are unable to normally retain some salts (sodium, potassium and magnesium). Main consequences of these renal leaks of salts are a tendency toward low blood pressure, hypokalemia and hypomagnesemia both contributing to cardiac and muscles symptoms.

NCT ID: NCT00822107 Completed - Gitelman Syndrome Clinical Trials

A Translational Approach to Gitelman Syndrome

Start date: January 2009
Phase: N/A
Study type: Interventional

This study will test the response to a single dose of thiazide diuretic as a diagnostic test for Gitelman syndrome. Individuals with hypokalemic alkalosis will be enrolled. After a baseline study, they will have the response to 50 mg hydrochlorothiazide on fractional chloride excretion examined.